OptiNose股票讨论区

$OptiNose(OPTN.US)$
NEWS
Optinose Announces $55 Million Registered Direct Offering

$Processa Pharmaceuticals(PCSA.US)$ $Barfresh Food(BRFH.US)$ $Intelligent Living Application(ILAG.US)$ $SuperCom(SPCB.US)$ $reAlpha Tech(AIRE.US)$ $OptiNose(OPTN.US)$
📊⚡️📊

$OptiNose(OPTN.US)$ SOPTN XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal
Polyps

$OptiNose(OPTN.US)$ Approved 🚀🚀🚀🚀

Last week’s PDUFAs:
$百济神州(BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$施贵宝(BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ®  + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$万达生物制药(VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ® 
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...

$OptiNose(OPTN.US)$ OptiNose (NASDAQ:OPTN) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 47.06 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $19.86 million which beat the analyst consensus estimate of $19.23 million by 3.30 percent. This is a 4.75 percent decrease over sales of $20.86 million the same period last year.

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Eyenovia(EYEN.US)$ $万达生物制药(VNDA.US)$ $Mirum Pharmaceuticals(MIRM.US)$ $Madrigal Pharmaceuticals(MDGL.US)$ $杰龙(GERN.US)$ $施贵宝(BMY.US)$ $2seventy bio(TSVT.US)$ $传奇生物(LEGN.US)$ $OptiNose(OPTN.US)$ $Orchard Therapeutics(ORTX.US)$ $默沙东(MRK.US)$ $Akebia Therapeutics(AKBA.US)$ $阿斯利康(AZN.US)$ $Liquidia(LQDA.US)$ $Esperion Therapeutics(ESPR.US)$ $再生元制药公司(REGN.US)$ $百济神州(BGNE.US)$